Entera Bio

Company Overview

Snapshot

Founded in September 2009, Entera Bio operates with 11–50 employees and has raised a total of $333.9M across 8 funding rounds from 7 investors. The company went public on NASDAQ in July 2018.

Business overview

Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics. The company's proprietary technology enhances the absorption of large molecules in the gastrointestinal tract, addressing challenges in oral drug delivery. Entera Bio is developing first-in-class, daily tablet protein and peptide replacement therapies for chronic diseases, aiming to provide injection-free treatment options for patients. It operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals and drug discovery and development.

Strategic signal

In May 2026, Entera Bio's EB613, a first-in-class oral PTH(1-34) anabolic for osteoporosis, had single tablet data selected for a late-breaking oral presentation at the ENDO 2026 Annual Meeting, with additional oral peptide pipeline data also accepted. This indicates significant progress and validation of its core technology in a major therapeutic area, suggesting potential for advanced clinical development and market entry.

Company Intelligence Q&A

What was a significant recent development for Entera Bio's EB613 program?

In May 2026, Entera Bio's EB613, a first-in-class oral PTH(1-34) anabolic for osteoporosis, had single tablet data selected for a late-breaking oral presentation at the ENDO 2026 Annual Meeting. Additional oral peptide pipeline data were also accepted for presentation.

What was the outcome of Entera Bio's Q1 2026 financial results?

In May 2026, Entera Bio announced its First Quarter 2026 Financial Results and provided updates across its oral peptide programs.

What was the key finding presented by Entera Bio regarding EB613 in September 2025?

In September 2025, Entera Bio presented positive effects of EB613 on both trabecular and cortical bone in postmenopausal women with osteoporosis at ASBMR 2025.

What new data did Entera Bio unveil for its oral GLP-2 therapy in September 2025?

In September 2025, Entera Bio unveiled promising PK data for its first oral GLP-2 therapy.

What was the nature of Entera Bio's collaboration with OPKO Biologics announced in September 2023?

In September 2023, Entera Bio announced a collaboration with OPKO Biologics to develop oral peptide tablet formulations for obesity and intestinal malabsorption syndromes.